Detalhe da pesquisa
1.
Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177 Lu-J591) for metastatic castration-resistant prostate cancer.
Cancer
; 125(15): 2561-2569, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31012963
2.
Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis.
Blood
; 122(11): 1881-6, 2013 Sep 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-23900239
3.
Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial.
Cancer
; 118(22): 5497-506, 2012 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22569804
4.
Targeted Radionuclide Therapy: A Historical and Personal Review.
Semin Nucl Med
; 50(1): 87-97, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31843064
5.
Possible axonal regrowth in late recovery from the minimally conscious state.
J Clin Invest
; 116(7): 2005-11, 2006 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-16823492
6.
Update on nuclear medicine imaging of neuroendocrine tumors.
Future Oncol
; 5(1): 75-84, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19243300
7.
Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model.
Radiology
; 246(2): 497-507, 2008 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-18227543
8.
Phase 1 Study of High-Specific-Activity I-131 MIBG for Metastatic and/or Recurrent Pheochromocytoma or Paraganglioma.
J Clin Endocrinol Metab
; 103(1): 213-220, 2018 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29099942
9.
Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement.
Leuk Lymphoma
; 48(2): 342-8, 2007 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17325895
10.
Investigation of the role of the base in the synthesis of [18F]FLT.
Appl Radiat Isot
; 65(12): 1350-8, 2007 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-17919915
11.
Radioactive Iodine Therapy of Differentiated Thyroid Carcinoma: Redesigning the Paradigm.
Mol Imaging Radionucl Ther
; 26(Suppl 1): 74-79, 2017 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28117291
12.
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.
J Clin Oncol
; 23(21): 4591-601, 2005 Jul 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-15837970
13.
Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas.
J Clin Oncol
; 23(30): 7565-73, 2005 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-16186600
14.
Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma.
J Clin Oncol
; 23(24): 5696-704, 2005 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-16110029
15.
Clinical utility of radiolabeled monoclonal antibodies in prostate cancer.
Clin Genitourin Cancer
; 4(4): 249-56, 2006 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-16729907
16.
Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity.
Clin Cancer Res
; 11(19 Pt 2): 7195s-7200s, 2005 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16203821
17.
Radioimmunotherapy of Metastatic Prostate Cancer with ¹77Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody.
Curr Radiopharm
; 9(1): 44-53, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-25771365
18.
Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.
J Clin Oncol
; 22(13): 2522-31, 2004 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15173215
19.
Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?
J Nucl Med
; 46(4): 634-41, 2005 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-15809486
20.
Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.
J Nucl Med
; 46(5): 850-8, 2005 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-15872360